Users of medicinal cannabis report a notable enhancement in their insomnia symptoms due to cannabinoid usage, and this research indicates a potential benefit of predominantly indica strains in comparison to predominant sativa strains and pure CBD in this particular demographic. Cannabinoids are regarded as effective across various genders and age groups (with no notable distinctions observed among different product forms), methods of ingestion, or gender categories. We analyzed data from 991 medicinal cannabis users suffering from insomnia across a total of 24,189 recorded sessions of cannabis usage.
Studies involving animals revealed that the modulation of the endocannabinoid (ECB) system impacted both activity and cognitive abilities, with some effects seemingly reliant on the light/dark cycle. This review intends to encapsulate the latest research regarding the ECB system — as well as the influence of cannabis on sleep regulation and cognitive functions. Future studies on PEA should strive to reveal the complex biochemical processes that connect the functioning of peroxisome proliferator-activated receptors , PPARs, to the detailed transmitter systems regulating sleep architecture and the sleep–wake cycle.
In one study REM sleep was increased in response to increased AEA , Méndez-Díaz et al., 2013,. Additionally — the authors used an event-related fMRI card-guessing paradigm to measure reward pathway activation. There was variability in the cannabis content used by participants in this study — as well as substantial differences in cannabis use frequency and method of use.
AASM condemns House passage of Sunshine Protection Act
To understand how cannabis-based medical products might affect insomnia symptoms, the authors of this study analyzed a CBD and sleep support explained set of 124 insomnia patients taking medical cannabis products. Prevalence and correlates of sleep-related problems in adults receiving medical cannabis for chronic pain. Specifically, the obtained data were from a large sample of medical cannabis users who use a variety of cannabis products for a variety of sleep-related issues.
The authors would like to express their deep appreciation to the staff and clinicians at Wholeness Center for their professionalism. The first is that in our experience lower doses appear to elicit an adequate clinical response. The treatment with CBD was in general well accepted, as judged by the clinicians’ and patients’ responses. These results demonstrated a more sustained response to anxiety than for sleep over time. Mean anxiety and sleep scores for adults using cannabidiol treatment.
Based on the data presented, the authors assert that “people with comorbid PTSD and SUD do not need to undergo a period of abstinence before addressing their PTSD.” An observational study collected data from Strainprint, a medical cannabis application where users recorded their symptoms of depression, anxiety, and stress over time. A significant limitation of this research is the absence of investigations into dose-response relationships. However, this study is limited by its high heterogeneity and an outlier study. Nonetheless — this study has limitations stemming from its substantial heterogeneity.
Conducted studies in Canada, including two RCTs with mostly male participants, showed varying outcomes for refreshing sleep, either resulting in improvements in total sleep or a decrease in nightmares among those using nabilone. The impact of cannabis on sleep and post-traumatic stress disorder is detailed in Table 5. In Table 4 (a distribution of 75% RCT studies and 25% cross-sectional design investigations of cannabis as an alternative treatment for patients dealing with insomnia and chronic pain is displayed), shared equally between North America and Europe. A chronological sequence of observational studies examining the influence of cannabis on sleep is presented. Experimental research studies that explore the effects of cannabis on sleep are arranged in chronological order of publication.